Samir Amany, Tawab Reda Abdel, El Tayebi Hend M
Molecular Pharmacology Research Group, Department of Pharmacology and Toxicology, German University in Cairo, Cairo 11835, Egypt.
Department of General Surgery, Ain Shams University, Cairo 11772, Egypt.
Oncol Lett. 2021 Aug;22(2):593. doi: 10.3892/ol.2021.12854. Epub 2021 Jun 7.
Long non-coding RNAs (lncRNAs) have attracted widespread attention as potential biological and pathological regulators. lncRNAs are involved in several biological processes in cancer. Triple negative breast cancer (TNBC) is characterized by strong heterogeneity and aggressiveness. At present, the implication of microRNAs (miRs) and lncRNAs in immunotherapy has been poorly studied. Nevertheless, the blockade of immune checkpoints, particularly that of the programmed cell-death protein-1/programmed cell-death ligand-1 (PD-L1) axis, is considered as a principle approach in breast cancer (BC) therapy. The present study aimed to investigate the interaction between immune-modulatory upstream signaling pathways of the PD-L1 transcript that could enhance personalized targeted therapy. MDA-MB-231 cells were transfected with miR-182-5p mimics followed by RNA extraction and cDNA synthesis using a reverse transcription kit, and the expression levels of the target genes were assessed by reverse transcription-quantitative PCR. Furthermore, the expression levels of target genes were measured in tissues derived from 41 patients with BC, including patients with luminal BC and TNBC, as well as their adjacent lymph nodes. The results revealed that the expression levels of miR-182-5p, PD-L1 and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) were upregulated in MDA-MB-231 cells and BC tissues. However, X-inactive specific transcript (XIST) expression was downregulated in cancer tissues and TNBC cells. Following co-transfection of cells with small interfering RNAs specific for each target gene and miR-182-5p antagomirs, the effect of miR-182-5p was abolished in the presence of lncRNAs. Therefore, the results of the present study indicated that although miR-182-5p exhibited an oncogenic effect, XIST exerted a dominant effect on the regulation of the PD-L1 signaling pathway via the inhibition of the oncogenic function of MALAT1.
长链非编码RNA(lncRNAs)作为潜在的生物和病理调节因子已引起广泛关注。lncRNAs参与癌症的多个生物学过程。三阴性乳腺癌(TNBC)具有高度异质性和侵袭性。目前,微小RNA(miRs)和lncRNAs在免疫治疗中的作用研究较少。然而,免疫检查点阻断,特别是程序性细胞死亡蛋白1/程序性细胞死亡配体1(PD-L1)轴的阻断,被认为是乳腺癌(BC)治疗的主要方法。本研究旨在探讨可增强个性化靶向治疗的PD-L1转录本免疫调节上游信号通路之间的相互作用。用miR-182-5p模拟物转染MDA-MB-231细胞,随后使用逆转录试剂盒进行RNA提取和cDNA合成,并通过逆转录定量PCR评估靶基因的表达水平。此外,还测量了41例BC患者(包括管腔型BC和TNBC患者)及其相邻淋巴结组织中靶基因的表达水平。结果显示,miR-182-5p、PD-L1和转移相关肺腺癌转录本1(MALAT1)在MDA-MB-231细胞和BC组织中的表达水平上调。然而,X染色体失活特异性转录本(XIST)在癌组织和TNBC细胞中的表达下调。在用针对每个靶基因的小干扰RNA和miR-182-5p拮抗剂共转染细胞后,在lncRNAs存在的情况下,miR-182-5p的作用被消除。因此,本研究结果表明,尽管miR-182-5p具有致癌作用,但XIST通过抑制MALAT1的致癌功能对PD-L1信号通路的调节发挥主导作用。